GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- Flexitol® 25% Urea Heel Balm – treatment of callus on heels and feet in diabetic patients
- Flexitol®10% Urea cream – urea based emollient (replaces Eucerin on formulary)
- Space Chamber Plus® – for use with MDIs (cost effective alternative)
- Compact Space Chamber Plus® – for use with MDIs (cost effective alternative)
- Evacal D3 – Prevention & treatment of osteoporosis - cost-effective alternative to Adcal D3 in Primary Care
- Budesonide Foam Enema – 2nd line option where steroid preparation is required. (hydrocortisone foam enema currently in short supply)
- Paravit-CF® - when patients are initiated or switched to this product, prescribers should ensure that existing preparations for individual ingredients that included in Paravit-CF are discontinued.
- Levonorgestrel IUD (Levosert®) 20mcg/24 hrs – intra-uterine Progesterone only contraceptive (licensed indications only)
- Doxylamine succinate & pyridoxine hcl 10mg/10mg tablets (Xonvea®) - nausea and vomiting of pregnancy in women who do not respond to conservative management
- Semaglutide: Ozempic®Insufficiently controlled Type 2 Diabetes.

Guidelines/Other

- Medicines Management Board Minutes
- Drug Safety Updates
- Nice Bites
- Prescribing Hot Topics
- Shared Care Guidelines
- New PrescQipp e-learning:
  1. Anticholinergic burden
  2. Reducing Opioid Prescribing in chronic pain
- Testosterone Shared Care Guideline
- Combined Adult and Child ADHD Shared Care Guideline
- Psoriasis – Biologic and High Cost Drug Pathway
- Lidocaine teething products – information for patients
- Training for Care Home Staff
- Nutritional Supplements in substance misusers – updated version
- Rifaximin prescribing guidance – updated
- Overactive Bladder Guideline – updated
- Gout Management Summary Guidelines – updated
- Hydroxychloroquine – Information for Prescribers

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- Liothyronine – remains BLACK traffic light. An IFR application can be made in exceptional circumstances.
- Padeliporin – untreated localised prostate cancer – not recommended by NICE TA546
- Vandetanib – medullary thyroid cancer – not recommended by NICE TA550

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- Amgevita - Adalimumab biosimilar allocated to ELHE – 1st line choice in new patients.
- Lenvatinib** – untreated advanced hepatocellular carcinoma – an option by NICE TA551
- Liposomal cytarabine-daunorubicin – untreated acute myeloid leukaemia – an option by NICE TA552
- Gemtuzumab ozogamicin** – untreated acute myeloid leukaemia – as an option by NICE TA545
- Pembrolizumab–adjuvant treatment of resected melanoma with high risk of recurrence - an option by NICE TA553 (Cancer Drugs Fund)
- Espranor® - buprenorphine oral lyophilisate – for use by Specialist Substance Misuse service only
- Tofacitinib – moderately severe active ulcerative colitis – an option by NICE TA547
- Tisagenlecleucel – relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years – an option by NICE TA554 (Cancer Drugs Fund)
- Free Style Libre – REMINDER to prescribers that this is RED Traffic Light and patients should not be advised to go to their GP.